| Proposed Ticker: IMSL | 3050 Science Park Road | |
| Exchange: NASDAQ-National Market | San Diego, California 92121 | |
| Industry: Manufacturing | (619) 677-0182 |
| All share information is proposed | ||||
| Type of Shares: | Common Shares | Filing Date: | 7/3/96 | |
| U.S. Shares Filed: | 3,000,000 | Filing Range: | $9.00 - $11.00 | |
| Non-U.S. Shares Filed: | 0 | Offering Amount: | $30,000,000 | |
| Primary Shares: | 3,000,000 | Expenses: | $600,000 | |
| Secondary Shares: | 0 | Shs Out After: | 12,984,477 | |
| Manager | Tier | Phone |
| PaineWebber Incorporated | Lead Manager | (212) 713-2626 |
| Needham & Company | Co-manager | (212) 371-8300 |
| Sutro & Company Inc. | Co-manager | (415) 445-8323 |
| Audited Income | Latest Unaudited Income | Prior Unaudited Income | Balance Sheet | ||
| 12/31/95 | 3/31/96 | 3/31/95 | 3/31/96 | ||
| Revenue: | $3.18 | $1.51 | $0.06 | Assets: | $7.85 |
| Net Income: | $0.13 | $0.44 | -$0.32 | Liabilities: | $1.07 |
| EPS: | $0.01 | $0.04 | -$0.04 | Equity: | $6.78 |
Note: Dollar amounts are in U.S. millions; Audited figures expressed as full year, unaudited figures are partial year | |||||
| Business Description |
| The company is a biopharmaceutical company dedicated to the discovery, development and commercialization of products based on proprietary technologies in the areas of ribozyme gene therapy and ribozyme-mediated gene functional analysis. The company intends to initiate a phase I clinical trial with its lead compund, HIVase I, in 1996. HIVase I is being developed through a collaboration with Pfizer, Inc., for the treatment of HIV-infected individuals. In addition, the company has three other ribozyme gene therapy programs in various stages of research and preclinical development for the prevention of coronary restenosis and the treatment of hepatitis C and hepatitis B viral infections. Ribozyme therapies can be based on i) ribozyme gene therapy which involves inserting specific sequences that lead to the production of ribozymes within the patient's cells or ii) synthetic, chemically modified ribozymes administered as drugs. The gene therapy approach to ribozyme therapy utilizes the patient's own cellular machinery to produce a constant and continuous supply of ribozymes inside the cell where the disease-causing gene is produced. |
| Use of Proceeds |
| Proceeds from the proposed offering will be used to fund research and development and for working capital and general corporate purposes. |
©1996 IPO Data Systems, Inc. - All rights reserved.